Skip to content

Patient experience and advocacy

TL;DR — Hypertension is the archetypal asymptomatic diagnosis: nothing hurts, the treatment can be felt while the disease cannot, and the benefit is statistical and decades away. The qualitative literature converges on that asymmetry. In a Swedish survey of 219 treated patients analysed thematically, limited understanding of the condition and fear of drug side effects recurred alongside health-system factors — short appointments, prescribing without conversation, and little individualisation (Malkon 2023, PMID 38106370). In Dutch interviews with community-dwelling people aged 74–93, participants rarely raised hypertension with their general practitioner despite having concerns, and the authors named the pattern a "conspiracy of silence" between patients who defer and clinicians who do not raise it (van Bussel 2019, PMID 31427342). Self-monitoring, the intervention most often offered as empowerment, is experienced ambivalently: a synthesis of 35 qualitative studies and 872 patients found it simultaneously enabling and a source of anxiety, a constant reminder of illness identity, and a financial burden (Natale 2023, PMID 36840919). Advocacy in this condition is unusual in being led by professional societies and public-health bodies rather than by patient-founded organisations, which is itself a consequence of the disease being invisible.

Method and ethics for this page: public sources only; themes reported in aggregate; no names or identifying details of private individuals; organisations verified by retrieving their websites on 2026-09-01. Full method in literature/patient-voice/README.md.

Themes from the qualitative literature

1. An asymptomatic diagnosis is hard to hold on to

Understanding of what hypertension is and why it is treated is limited even among people already taking medication (Malkon 2023, PMID 38106370). Retrospective accounts of the period before diagnosis describe stress, life disruption and somatic attributions rather than a sense of developing illness (Shamsi 2017, PMID 28461866). In settings where hypertension goes untreated, patients' own explanations centre on the absence of symptoms and on competing priorities (Rahmawati 2018, PMID 28669227). A structural corollary appears in the earliest literature on labelling: being told one is hypertensive has measurable effects on work and social function independent of any physiological change (Johnston 1984, PMID 6725496).

2. Medication is experienced as the illness

Fear of side effects is one of the two most consistent themes across studies and settings (Malkon 2023, PMID 38106370; Tsiantou 2010, PMID 20859460). Habit-formation interviews in Los Angeles found that experiencing side effects functioned as both a barrier and a facilitator of routine-building, depending on how the person interpreted them; frequent regimen changes and polypharmacy disrupted habit formation, while stable daily anchors, pillboxes and visual reminders supported it (Ghai 2024, PMID 38991671). Participants in the QUARTET quadpill trial gave their own views on ultra-low-dose combination therapy (Kovoor 2024, PMID 38744907), which is directly relevant to whether the single-pill strategies in pharmacological therapy are acceptable as well as effective.

3. Self-monitoring is empowering and burdensome at once

The thematic synthesis of 35 studies identified four themes: enabling autonomy and empowerment (access to accurate data, motivation for lifestyle change, diligence in medication-taking); reassurance and convenience (a sense of security, fewer appointments); confusion and stress (anxiety over "bad" numbers, a constant reminder of illness identity, feeling disregarded by clinicians, low confidence in interpreting readings, uncertainty about targets and frequency, doubts about device reliability); and financial and operational burden of the device (Natale 2023, PMID 36840919). Telemonitoring adds its own texture — patients and professionals value it differently (Baratta 2022, PMID 35687380; Strandberg 2023, PMID 38746569), and embedded qualitative work in TASMINH4 examined how self-monitoring is actually used (Grant 2019, PMID 31262847). Postpartum self-management, where the intervention worked best clinically, has its own implementation study (Cairns 2020, PMID 32517785). The lesson mirrors the trial evidence: self-monitoring without a titration pathway attached is burden without benefit (Tucker 2017, PMID 28926573).

4. Cost and access shape adherence more than motivation does

Cost-related medication non-adherence remains prevalent among US adults with hypertension (Reddy 2025, PMID 40285540), and the decision to underuse medication under financial pressure depends on drug characteristics as well as price (Piette 2006, PMID 16765278). In low- and middle-income settings, availability, distance, cost and the structure of the clinic dominate patient accounts — in Tanzania (Edward 2021, PMID 34407820), rural India (Gupta 2019, PMID 30809390), Delhi (Basu 2022, PMID 32938210), Uganda (Najjuma 2020, PMID 32897274) and Nigeria (Oyibo 2025, PMID 40845429). India's pooled non-adherence prevalence across 18,808 patients has been quantified (Sandeep 2025, PMID 40926604). The COVID-19 period disrupted chronic-disease care and patients described the consequences directly (Singh 2021, PMID 34145019).

5. Culture, community and trust

Adherence accounts among Black women in the US emphasise trust, competing responsibilities and prior experience of the health system (Abel 2022, PMID 35171867); similar themes appear among Black African and Black Caribbean residents in south-east London (Yogarajah 2025, PMID 40389279) and in ethnographic work on religiosity and spirituality in medication-taking (Abdul Wahab 2021, PMID 34675490). Neighbourhood perceptions — safety, food environment, stress — feature in low-income Black women's accounts of their own hypertension (Al-Bayan 2016, PMID 27733142). Post-trial interviews with barbershop-trial participants, barbers and pharmacists explain why that model worked where clinic-based care had not (Kohrman 2024, PMID 38723012) — see adherence and implementation. Adherence in HIV care carries a further layer of competing treatment priorities (Ayodele 2026, PMID 42239779).

6. Physical activity is wanted but not resourced

A synthesis of 17 qualitative studies mapped physical-activity experience onto capability (age, comorbidity, knowledge and skills), opportunity (time, environment, resources, social support) and motivation (self-efficacy, pursuit of health, prior experience of activity) (Li 2024, PMID 39407187). Most of the identified barriers are environmental rather than motivational, which is consistent with the durability asymmetry described in lifestyle and dietary management.

7. Older people want a conversation that is not happening

Interviewees aged 74–93 wanted to discuss tailoring, deprescribing and side-effect reduction, and expected clinicians to be more transparent about how much benefit treatment actually delivers; they anticipated regret if medication were reduced and something happened. Clinicians are known to be equally hesitant to raise it (van Bussel 2019, PMID 31427342). Given that OPTIMISE showed short-term deprescribing to be feasible in this age group (Sheppard 2020, PMID 32453368) and that harm concentrates in frailty (Sheppard 2023, PMID 37075078), this silence has direct clinical consequences — see special populations.

Organisations and campaigns

Verified by retrieving each site on 2026-09-01. Full directory with access details in literature/patient-voice/organizations.md.

Organisation Scope Role
World Hypertension League Global, non-governmental Prevention and control of hypertension worldwide; convenes World Hypertension Day (World Hypertension League — "Home", https://www.whleague.org/, accessed 2026-09-01)
International Society of Hypertension Global professional society Global practice guidelines; runs May Measurement Month (International Society of Hypertension, https://ish-world.com/, accessed 2026-09-01; May Measurement Month, https://www.maymeasure.org/, accessed 2026-09-01)
Blood Pressure UK United Kingdom The clearest example of a dedicated patient-facing blood-pressure charity (Blood Pressure UK, https://www.bloodpressureuk.org/, accessed 2026-09-01)
British Heart Foundation United Kingdom Public information on high blood pressure within a general cardiovascular charity (BHF — "High blood pressure (Hypertension)", https://www.bhf.org.uk/informationsupport/risk-factors/high-blood-pressure, accessed 2026-09-01)
Hypertension Canada Canada Guidelines plus professional and public education (Hypertension Canada, https://hypertension.ca/, accessed 2026-09-01)
European Society of Hypertension Europe Guidelines, measurement standards (European Society of Hypertension, https://www.eshonline.org/, accessed 2026-09-01)
Heart Foundation (Australia) Australia Research, advocacy, awareness and support (Heart Foundation, https://www.heartfoundation.org.au/, accessed 2026-09-01)
World Heart Federation Global Cardiovascular advocacy including blood pressure (World Heart Federation, https://world-heart-federation.org/, accessed 2026-09-01)
Resolve to Save Lives Global health NGO Hypertension control is one of its principal programmes (Resolve to Save Lives, https://resolvetosavelives.org/, accessed 2026-09-01)
WHO HEARTS technical package Global, intergovernmental The implementation framework behind several national programmes (WHO — "HEARTS: Technical package for cardiovascular disease management in primary health care", https://www.who.int/teams/noncommunicable-diseases/hearts-technical-package, accessed 2026-09-01)
PAHO HEARTS in the Americas Americas Country-led regional implementation of HEARTS (PAHO — "HEARTS in the Americas", https://www.paho.org/en/hearts-americas, accessed 2026-09-01)
STRIDE BP Global Independent registry of validated blood-pressure measuring devices — the practical answer to the unvalidated-device problem (STRIDE BP, https://www.stridebp.org/, accessed 2026-09-01)
NHLBI (US) United States, governmental Public information (NHLBI — "High Blood Pressure", https://www.nhlbi.nih.gov/health/high-blood-pressure, accessed 2026-09-01)
NHS (UK) United Kingdom, governmental Public information (NHS — "High blood pressure", https://www.nhs.uk/conditions/high-blood-pressure/, accessed 2026-09-01)

The structural observation worth recording: unlike fibromyalgia or rare diseases, hypertension has very few patient-founded advocacy organisations. Its advocacy is carried by professional societies, cardiovascular charities and public-health agencies. That is a rational response to an asymptomatic condition with no distinct patient identity — but it means the patient voice in this field reaches the literature mainly through qualitative research commissioned by clinicians, not through organised patient advocacy.

What patients say they want, in aggregate

  1. To understand what the number means and what treatment actually buys them, in absolute terms (Malkon 2023, PMID 38106370; van Bussel 2019, PMID 31427342).
  2. Fewer, simpler pills — which the single-pill combination evidence supports (Kovoor 2024, PMID 38744907; Chow 2021, PMID 34469767).
  3. Help interpreting home readings, not just a device (Natale 2023, PMID 36840919).
  4. Affordable, reliably available medication (Reddy 2025, PMID 40285540; Edward 2021, PMID 34407820).
  5. A conversation about stopping or reducing treatment when the balance shifts (van Bussel 2019, PMID 31427342).
  6. Care delivered where they already are (Kohrman 2024, PMID 38723012; Victor 2018, PMID 29527973).

Open questions

  • The PubMed search repeated on 2026-09-01 located treatment-satisfaction, adherence and quality-of-life instruments but no generally used hypertension-specific treatment-burden measure; trials therefore usually measure pressure and adverse events rather than what patients describe as the main costs (Natale 2023, PMID 36840919).
  • Does explaining absolute rather than relative risk change adherence? This has been tested: 210 adults with mild hypertension were randomised to individualised counselling that included 10-year cardiovascular risk, absolute risk reduction, adverse effects and cost versus general counselling. Medication use was 65.0% versus 57.9% (OR 1.35, 95% CI 0.77–2.36) and adherence 43.7% versus 40.2% (OR 1.15, 0.67–2.00), neither significant (Di 2020, PMID 31473598). A smaller three-arm cardiovascular-risk-communication trial also found no significant risk-score effect (Singhal 2024, PMID 38948564). The evidence gap as of 2026-09-01 is not absence of a trial but absence of a well-powered trial isolating absolute versus relative benefit framing.
  • Why does self-monitoring produce anxiety in some people and empowerment in others, and can the difference be predicted before a device is issued? (Natale 2023, PMID 36840919)
  • The organisation search repeated on 2026-09-01 found one clear dedicated patient-facing charity (Blood Pressure UK) amid predominantly professional, cardiovascular-charity and public-health bodies. Does that documented advocacy structure affect research priorities, and would a patient-led agenda differ?
  • Older people and their clinicians each wait for the other to raise deprescribing (van Bussel 2019, PMID 31427342). What clinical prompt would break that, and does breaking it improve outcomes?

References

  1. Malkon S, et al. A Qualitative Study on Patients' Views on Hypertension and Antihypertensive Medications. Patient Prefer Adherence. 2023;17:3331-3339. PMID 38106370
  2. van Bussel E, et al. Hypertension management: experiences, wishes and concerns among older people—a qualitative study. BMJ Open. 2019;9:e030742. PMID 31427342
  3. Natale P, et al. Perspectives and Experiences of Self-monitoring of Blood Pressure Among Patients With Hypertension: A Systematic Review of Qualitative Studies. Am J Hypertens. 2023;36:372-384. PMID 36840919
  4. Shamsi A, et al. Life experiences of patients before having hypertension: a qualitative study. Electron Physician. 2017;9:3925-3933. PMID 28461866
  5. Rahmawati R, et al. Understanding untreated hypertension from patients' point of view: a qualitative study in rural Yogyakarta province, Indonesia. Chronic Illn. 2018;14:228-240. PMID 28669227
  6. Johnston ME, et al. Effects of labelling on income, work and social function among hypertensive employees. J Chronic Dis. 1984;37:417-23. PMID 6725496
  7. Tsiantou V, et al. Factors affecting adherence to antihypertensive medication in Greece: results from a qualitative study. Patient Prefer Adherence. 2010;4:335-43. PMID 20859460
  8. Ghai I, et al. Barriers and facilitators of habit building for long-term adherence to antihypertensive therapy. BMJ Open. 2024;14:e079401. PMID 38991671
  9. Kovoor JG, et al. Participants' views of ultra-low dose combination therapy for high blood pressure. J Hum Hypertens. 2024;38:516-522. PMID 38744907
  10. Baratta J, et al. Patient and Health Professional Perceptions of Telemonitoring for Hypertension Management: Qualitative Study. JMIR Form Res. 2022;6:e32874. PMID 35687380
  11. Strandberg S, et al. Self-care management and experiences of using telemonitoring. Int J Nurs Stud Adv. 2023;5:100149. PMID 38746569
  12. Grant S, et al. Using mHealth for the management of hypertension in UK primary care: TASMINH4 embedded qualitative study. Br J Gen Pract. 2019;69:e612-e620. PMID 31262847
  13. Cairns AE, et al. Implementing self-management: women's experiences of a postpartum hypertension intervention (SNAP-HT). Trials. 2020;21:508. PMID 32517785
  14. Tucker KL, et al. Self-monitoring of blood pressure in hypertension: individual patient data meta-analysis. PLoS Med. 2017;14:e1002389. PMID 28926573
  15. Reddy RV, et al. Cost-related medication nonadherence in adults with hypertension in the USA. Int J Qual Health Care. 2025;37. PMID 40285540
  16. Piette JD, et al. Medication characteristics beyond cost alone influence decisions to underuse pharmacotherapy. J Clin Epidemiol. 2006;59:739-46. PMID 16765278
  17. Edward A, et al. Patient and healthcare provider perspectives on adherence with antihypertensive medications in Tanzania. BMC Health Serv Res. 2021;21:834. PMID 34407820
  18. Gupta S, et al. Qualitative Study of Barriers to Adherence to Antihypertensive Medication among Rural Women in India. Int J Hypertens. 2019;2019:5749648. PMID 30809390
  19. Basu S, et al. Determinants of adherence to antihypertensive treatment in a primary care clinic in Delhi, India: a qualitative study. Chronic Illn. 2022;18:295-305. PMID 32938210
  20. Najjuma JN, et al. Adherence to Antihypertensive Medication: An Interview Analysis of Southwest Ugandan Patients' Perspectives. Ann Glob Health. 2020;86:58. PMID 32897274
  21. Oyibo P, et al. Barriers and Enablers of Antihypertensive Adherence in Delta State, Nigeria. West Afr J Med. 2025;42:240-247. PMID 40845429
  22. Sandeep M, et al. Prevalence of Non-Adherence to Antihypertensive Medication in India. Curr Hypertens Rev. 2025;21:231-246. PMID 40926604
  23. Singh K, et al. Patient experiences and perceptions of chronic disease care during the COVID-19 pandemic in India: a qualitative study. BMJ Open. 2021;11:e048926. PMID 34145019
  24. Abel WM, et al. Antihypertensive medication adherence and persistence among Black women: A qualitative study. Nurse Pract. 2022;47:40-47. PMID 35171867
  25. Yogarajah N, et al. Exploring adherence to antihypertensive medication in Black African and Black Caribbean residents in South East London. BJGP Open. 2025;9. PMID 40389279
  26. Abdul Wahab NA, et al. Exploring Culture, Religiosity and Spirituality Influence on Antihypertensive Medication Adherence. Patient Prefer Adherence. 2021;15:2249-2265. PMID 34675490
  27. Al-Bayan M, et al. Neighborhood perceptions and hypertension among low-income black women: a qualitative study. BMC Public Health. 2016;16:1075. PMID 27733142
  28. Kohrman N, et al. A qualitative analysis of post-hoc interviews with multilevel participants of a randomized controlled trial. PLoS One. 2024;19:e0303075. PMID 38723012
  29. Ayodele V, et al. Managing Blood Pressure Beyond Viral Suppression: patient and provider perspectives on antihypertensive adherence in HIV care. Res Sq. 2026. PMID 42239779
  30. Li Q, et al. Physical activity experience of patients with hypertension: a systematic review and synthesis of qualitative literature. BMC Public Health. 2024;24:2826. PMID 39407187
  31. Sheppard JP, et al. Effect of Antihypertensive Medication Reduction vs Usual Care (OPTIMISE). JAMA. 2020;323:2039-2051. PMID 32453368
  32. Sheppard JP, et al. The association between antihypertensive treatment and serious adverse events by age and frailty. PLoS Med. 2023;20:e1004223. PMID 37075078
  33. Chow CK, et al. Initial treatment with a single pill containing quadruple combination of quarter doses (QUARTET). Lancet. 2021;398:1043-1052. PMID 34469767
  34. Victor RG, et al. A Cluster-Randomized Trial of Blood-Pressure Reduction in Black Barbershops. N Engl J Med. 2018;378:1291-1301. PMID 29527973
  35. M Yatim H, et al. Factors influencing patients' hypertension self-management and sustainable self-care practices: a qualitative study. Public Health. 2019;173:5-8. PMID 31207425
  36. Bane C, et al. The journey to concordance for patients with hypertension: a qualitative study in primary care. Pharm World Sci. 2007;29:534-40. PMID 17487567
  37. Mondesir FL, et al. Patient Perspectives on Factors Influencing Medication Adherence Among People with CHD and CHD Risk Factors. Patient Prefer Adherence. 2019;13:2017-2027. PMID 31819383
  38. Di M, et al. Lack of effects of evidence-based, individualised counselling on medication use in insured patients with mild hypertension in China: a randomised controlled trial. BMJ Evid Based Med. 2020;25:102-108. PMID 31473598
  39. Singhal K, et al. A parallel-arm randomised control trial to study the effects of risk communication methods for prevention of cardiovascular diseases: EFFRICO trial. J Family Med Prim Care. 2024;13:1922-1930. PMID 38948564

Non-journal sources

  • World Hypertension League — "Home", https://www.whleague.org/, accessed 2026-09-01
  • International Society of Hypertension, https://ish-world.com/, accessed 2026-09-01
  • May Measurement Month, https://www.maymeasure.org/, accessed 2026-09-01
  • Blood Pressure UK, https://www.bloodpressureuk.org/, accessed 2026-09-01
  • British Heart Foundation — "High blood pressure (Hypertension) — causes and symptoms", https://www.bhf.org.uk/informationsupport/risk-factors/high-blood-pressure, accessed 2026-09-01
  • Hypertension Canada, https://hypertension.ca/, accessed 2026-09-01
  • European Society of Hypertension, https://www.eshonline.org/, accessed 2026-09-01
  • Heart Foundation (Australia), https://www.heartfoundation.org.au/, accessed 2026-09-01
  • World Heart Federation, https://world-heart-federation.org/, accessed 2026-09-01
  • Resolve to Save Lives, https://resolvetosavelives.org/, accessed 2026-09-01
  • World Health Organization — "HEARTS: Technical package for cardiovascular disease management in primary health care", https://www.who.int/teams/noncommunicable-diseases/hearts-technical-package, accessed 2026-09-01
  • Pan American Health Organization — "HEARTS in the Americas", https://www.paho.org/en/hearts-americas, accessed 2026-09-01
  • STRIDE BP, https://www.stridebp.org/, accessed 2026-09-01
  • National Heart, Lung, and Blood Institute — "High Blood Pressure", https://www.nhlbi.nih.gov/health/high-blood-pressure, accessed 2026-09-01
  • NHS — "High blood pressure", https://www.nhs.uk/conditions/high-blood-pressure/, accessed 2026-09-01